TORONTO--(BUSINESS WIRE)--

Antibe Therapeutics Inc. ("Antibe") (TSXV: ATE, OTCQX: ATBPF) today announced that its subsidiary Citagenix Inc. (“Citagenix”) has launched PentOS OI™ Max for the dental biologics market. PentOS OI™ Max is the newest member of the PentOS OI™ family of bone grafts for oral and maxillofacial surgery.

PentOS OI™ Max is an inductive collagen matrix that can be mixed with the clinician’s choice of patient derived concentrates (including stem cells and blood components). Osteoinductivity is demonstrated in each lot in both in vivo and in vitro assays using independent laboratories. In vitro testing demonstrated levels of bone morphogenetic protein (“BMP”) up to 40-times that of the control. BMP is a naturally occurring growth factor found in the human body and plays a crucial role in bone formation. In vivo testing demonstrates all five elements of bone formation are present in our PentOS OI™ grafts: chondrocytes, osteocytes, bone marrow cells, cartilage, and new bone. In vitro studies also demonstrated excellent cell viability and proliferation.

“Citagenix continues to augment its portfolio with the addition of high-quality products that support optimal patient outcomes at a competitive price point,” said Dan Legault, Antibe’s CEO. “Being the ‘portfolio-of-choice’ for dentists and oromaxillofacial surgeons is important to our global growth strategy and is supported by an active business development funnel.”

PentOS OI™ Max will be offered in the Canadian market through our direct sales force and globally via our network of distribution partners. To learn more about the PentOS OI™ suite of products, please visit the product website: www.PentOS-OI.com.

About Antibe Therapeutics Inc.

Antibe develops safer medicines for pain and inflammation. Antibe’s technology involves linking a hydrogen sulfide-releasing molecule to an existing drug to produce a patented, improved medicine. Antibe’s lead drug, ATB-346, targets the global need for a safer drug for chronic pain and inflammation. ATB-352, the second drug in Antibe’s pipeline, targets the urgent global need for a safer, non-addictive analgesic for treating severe acute pain, while ATB-340 is a GI-safe derivative of aspirin. www.antibethera.com.

Antibe’s subsidiary, Citagenix Inc. (“Citagenix”), is a leader in the sales and marketing of tissue regenerative products servicing the orthopedic and dental marketplaces. Since its inception in 1997, Citagenix has become the largest source of knowledge and experience in the Canadian medical device industry. Citagenix Inc. is active in 15 countries, operating in Canada through its direct sales teams, and internationally via a network of distributor partnerships. www.citagenix.com.

Forward Looking Information

This news release includes certain forward-looking statements, which may include, but are not limited to, the completion of financing transactions and the licensing and development of drugs and medical devices. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions "will", "anticipate", "believe", "plan", "estimate", "expect", "intend", "propose" and similar expressions. Forward-looking statements involve known and unknown risks and uncertainties that could cause actual results, performance, or achievements to differ materially from those expressed or implied in this news release. Factors that could cause actual results to differ materially from those anticipated in this news release include, but are not limited to, the Company’s ability to secure additional financing, its ability to execute its business strategy and successfully compete in the market, and risks associated with drug and medical device development generally. Antibe Therapeutics Inc. assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those reflected in the forward-looking statements except as required by applicable law.

View source version on businesswire.com: http://www.businesswire.com/news/home/20170131005452/en/